Pubblicazioni Scientifiche

1- Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy;

Martina Bonechi1, Francesca Galardi1, Chiara Biagioni2, Francesca De Luca1, Mattias Bergqvist3, Magnus Neumüller3, Cristina Guarducci1, Giulia Boccalini1, Stefano Gabellini1, Ilenia Migliaccio1, Angelo Di Leo1,4, Marta Pestrin1,4 and Luca Malorni1,4

1“Sandro Pitigliani” Translational Research Unit, Hospital of Prato, Prato, Italy 2Bioinformatics Unit, Hospital of Prato, Prato, Italy 3Biovica International, Uppsala Science Park, Uppsala, Sweden 4“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Prato, Italy

Oncotarget. 2018; 9:16389-16399. DOWNLOAD PDF

 

2- Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

L Malorni, G Curigliano, A M Minisini, S Cinieri, C A Tondini, K D’Hollander, G Arpino, A Bernardo, A Martignetti, C Criscitiello, F Puglisi, M Pestrin, G Sanna, E Moretti, E Risi, C Biagioni, A McCartney, L Boni, M Buyse, I Migliaccio, L Biganzoli, A Di Leo;

Annals of Oncology, , mdy214, https://doi.org/10.1093/annonc/mdy214